FLUIDDA introduces RespiNet, a model for automated segmentation of lung structures. At the ECR 2023 conference in Vienna, FLUIDDA presents their deep learning model for the segmentation of the lobes and airway... View Article
Novel outcome measures for cystic fibrosis in a changing world Very recently Eline Lauwers, working for Fluidda in Belgium, defended a dissertation called: “Novel outcome measures for cystic fibrosis” to acquire... View Article
The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. According to WHO estimates, 65 million people... View Article
Due to Brexit, the United Kingdom is updating its medical device regulations and introducing a new route (UKCA marking) to place medical devices on the UK market. The new legislative... View Article
“In the respiratory space, the use of technology is still at a fairly low level. The gold standard is still spirometry. It is time to reassess and see if technology can be used in a way that really improves... View Article
On Friday October 7 at 2 PM EST, Jan De Backer CEO of Fluidda, will present at the RESCON-summit in New York. The presentation is entitled: “In-vitro/In-silico bio-equivalence trials as... View Article
Fluidda organized a Team Building in the Belgian Ardennes for its staff. Because the company operates worldwide and is growing rapidly, several employees had never met each other in person,... View Article
Fluidda and Aptar Pharma Announce Exclusive Collaboration to Help Accelerate Regulatory Pathway for Orally Inhaled Products Kontich, Belgium, September 22, 2022 – Fluidda, leader in the field of Functional Respiratory... View Article
FRI in critical care: challenges and opportunities Functional Respiratory Imaging (FRI) did not have a place in critical care before the COVID-19 pandemic, but as healthcare systems were overloaded with... View Article
In a recently published systematic literature review, members of PVRI Innovative Drug Development Initiative’s Sequelae of COVID-19 Workstream, including Fluidda CEO Jan De Backer and CSO Ben Lavon, sought to... View Article